Last update 21 Nov 2024

ZN-A-1041

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
+ [4]
Target
Mechanism
HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists)
Inactive Indication-
Inactive Organization-
Drug Highest PhasePhase 1
First Approval Date-
RegulationBreakthrough Therapy (CN)
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Malignant Solid NeoplasmPhase 1
CN
15 Oct 2020
HER2 Positive Breast CancerPhase 1
ES
15 Oct 2020
HER2 Positive Breast CancerPhase 1
AU
15 Oct 2020
HER2 Positive Breast CancerPhase 1
US
15 Oct 2020
HER2 Positive Breast CancerPhase 1
FR
15 Oct 2020
HER2 Positive Breast CancerPhase 1
CN
15 Oct 2020
HER2 Positive Breast CancerPhase 1
GB
15 Oct 2020
HER2 Positive Breast CancerPhase 1
NZ
15 Oct 2020
HER2 Positive Solid TumorsPhase 1
CN
15 Oct 2020
HER2 Positive Solid TumorsPhase 1
US
15 Oct 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
55
(T-DM1 With Palbociclib)
itxllxufay(fmpltkwjso) = pdruucwfnx kfbsodnwbw (tfcthehzme, wqjgasnomz - tlhphiwmgx)
-
24 Jul 2024
(Single Agent T-DM1)
itxllxufay(fmpltkwjso) = zuijbgdwwq kfbsodnwbw (tfcthehzme, jswrgyzuap - bjfhjoidsk)
Not Applicable
57
(awwnzmgwko) = wtyevkjsns edzmebfbhx (pxlthuanvj )
-
31 May 2023
(awwnzmgwko) = kmutmcrrbm edzmebfbhx (pxlthuanvj )
Not Applicable
Adjuvant
HER2-positive
202
tdffgcguav(pvxkzippjh) = Overall, 320 T-DM1-related AEs of any grade were registered in 105 pts (52%). G3 AEs were observed in 11 pts (5.4%), while there were no G4-G5 AEs. Most prevalent AEs of any grade were transaminases increase (19.8%), thrombocytopenia (15.3%), nausea and vomiting (13.3%), fatigue (10.9%), myalgia and arthralgia (7.4%), peripheral neuropathy (6.4%), and neutropenia (5%). For 42 out of 202 pts (20.8%), T-DM1 was reduced in dose, delayed or discontinued due to toxicity. jvttvmyozc (zudihvvnvd )
Positive
12 May 2023
Not Applicable
-
iueaqecrho(mzjkiawpww) = cosvoqkujv ewzawjgvgx (kaoxnudbie )
-
01 Nov 2021
Not Applicable
-
(onvhdqxmgz) = ifbvegqoly pnihvhahdu (usqygpcpdb )
-
10 Sep 2021
(mpgljbqjcf) = jxvphitvmo vmbgwofpgg (hlccrsklmb )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free